330-94-9

Basic information

• Product Name: 4-(4-FLUOROPHENYL)-3-THIOSEMICARBAZIDE
• Synonyms: SPECS AN-689/41741342;4-FLUOROPHENYLTHIOSEMICARBAZIDE;4-(4-FLUOROPHENYL)THIOSEMICARBAZIDE;4-(4-FLUOROPHENYL)-3-THIOSEMICARBAZIDE;4-(4-Fluorophenyl)-3-thiosemicarbazide 97%;4-(4-Fluorophenyl)-3-thiosemicarbazide97%;4-(4-Fluorophenyl)thiosemicarbazide 97%;N-(4-Fluorophenyl)hydrazinecarbothioamide, 1-Amino-3-(4-fluorophenyl)thiourea
• CAS NO: 330-94-9
• Molecular Formula: C₇H₈FN₃S
• Molecular Weight: 185.22
• Mol File: 330-94-9.mol
• Article Data: 31

Chemical Properties

• Melting Point: 171 °C
• Boiling Point: 285°C at 760 mmHg
• Flash Point: 126.2°C
• Appearance: /
• Density: 1.418g/cm³
• Vapor Pressure: 0.00287mmHg at 25°C
• Refractive Index: 1.696
• Water Solubility: Insoluble in water.
• BRN: 2804705
• CAS DataBase Reference: 4-(4-FLUOROPHENYL)-3-THIOSEMICARBAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUOROPHENYL)-3-THIOSEMICARBAZIDE(330-94-9)
• EPA Substance Registry System: 4-(4-FLUOROPHENYL)-3-THIOSEMICARBAZIDE(330-94-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 22-36/37-45
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: II
• Hazardous Substances Data: 330-94-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H8FN3S/c8-5-1-3-6(4-2-5)10-7(12)11-9/h1-4H,9H2,(H2,10,11,12)

Upstream product

• 1544-68-9 4-fluorophenyl isothiocyanate 
• 75-15-0 carbon disulfide 
• 371-40-4 4-fluoroaniline 
• 502756-12-9 1-(tert-butoxycarbonyl)-4-(4'-fluorophenyl)-3-thiosemicarbazide 
• 19182-34-4 ammonium p-fluorophenyldithiocarbamate 
• 1613375-24-8 C₉H₇FNO₂S₂^(1-)*Na⁽¹⁺⁾ 

Downstream Products

• 849-85-4 piperonal-[4-(4-fluoro-phenyl)-thiosemicarbazone] 
• 404-57-9 1-(4-chloro-phenylcarbamoyl)-4-(4-fluoro-phenyl)-thiosemicarbazide 
• 459-12-1 1-(4-ethoxy-phenylcarbamoyl)-4-(4-fluoro-phenyl)-thiosemicarbazide 
• 14731-24-9 5-(4-fluoro-anilino)-3H-[1,3,4]thiadiazole-2-thione 
• 16167-63-8 4-methoxy-benzaldehyde 4-(4-fluoro-phenyl)-thiosemicarbazone 
• 16113-37-4 4-(4-fluorophenyl)-1-[(2-hydroxyphenyl)methylidene]-3-thiosemicarbazide 
• 16113-38-5 4-dimethylamino-benzaldehyde 4-(4-fluoro-phenyl)-thiosemicarbazone 
• 485354-41-4 C₁₅H₁₀BrFN₄OS 
• 948998-10-5 (Z)-2-(5-fluoro-2-oxoindolin-3-ylidene)-N-(4-fluorophenyl)hydrazinecarbothio amide 
• 485383-26-4 (Z)-N-(4-fluorophenyl)-2-(5-nitro-2-oxoindolin-3-ylidene)hydrazinecarbothio amide 

Relevant articles and documents

Preparation and application of thiosemicarbazone compound

The invention discloses a thiosemicarbazone compound, and biological activity analysis is carried out on the thiosemicarbazone compound. The invention also discloses application of the thiosemicarbazone compound in preparation of antibacterial drugs. According to the invention, important intermediates 6a-6h are synthesized from hydrazine hydrate and react with adamantane benzaldehyde respectivelyto synthesize eight adamantane aromatic aldehyde thiosemicarbazone compounds, the structures of the compounds can be confirmed by infrared, nuclear magnetic hydrogen spectrum, carbon spectrum and massspectrum methods, and the antibacterial activity of the compounds is tested in vitro. The result shows that the compound has a good antibacterial effect on escherichia coli and bacillus subtilis.

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE

The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds.